Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02814643 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 103
- Enrollment target
NCT02814643 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 103 participants.
The verdict
NCT02814643, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 103 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of a fixed dose of benralizumab administered subcutaneously (SC) on antibody responses following seasonal influenza virus vaccination
Interventions
- DRUG Benralizumab
- DRUG Benralizumab Placebo
- DRUG Seasonal influenza virus vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2017-01-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02814643
The ClinicalTrials.gov registry entry for NCT02814643 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Benralizumab is the first listed.
NCT02814643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02814643 about?
NCT02814643 is a clinical study titled "Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma". This is a randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of a fixed dose of benralizumab administered subcutaneously (SC) on antibody responses following seasonal influenza virus vaccination
What is the current status of trial NCT02814643?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 103 participants. The study started on 2016-07-01. Estimated completion is 2017-01-24.
What interventions are being tested in trial NCT02814643?
The interventions under investigation include: Benralizumab (DRUG), Benralizumab Placebo (DRUG), Seasonal influenza virus vaccine (DRUG).
Who is sponsoring clinical trial NCT02814643?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.